Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

• Main Authors: Yi Long Wu, Masahiro Fukuoka, Tony S.K. Mok, Nagahiro Saijo, Sumitra Thongprasert, James C.H. Yang, Da Tong Chu, Jin Ji Yang, Yuri Rukazenkov
• Format: Journal
• Published: 2018
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879884557&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/47786
• Institution: Chiang Mai University

Background: In IPASS (NCT00322452), progression-free survival (PFS, primary endpoint) was significantly longer with first-line gefitinib versus carboplatin/paclitaxel in never/light ex-smokers with advanced pulmonary adenocarcinoma in Asia, both in the overall intent-to-treat (ITT) population and in...